Trinity College Dublin and St James s Hospital, Dublin clinical trials reported efficacy and safety results of upadacitinib compared with placebo for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents. This pivotal Global Phase 3 study involved 1,600 patients and took place over a two-year period. Results show the drug to so far be the most effective treatment for atopic dermatitis in clinical trials.